A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Despite boasting a new owner, the Indiana manufacturing plant Novo Nordisk picked up as part of its parent company's Catalent ...

Whether it’s a cook, a home health aide, or a direct support professional, domestic workers are critical for so many people ...

The plant — which was acquired last year by Novo Nordisk and has a history of troubled inspections — was cited for having cat hair, pests, and bacteria, a recent FDA inspection showed.

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

The FDA has identified critical lapses at a production facility operated by Novo Nordisk that is used by several drugmakers, ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

A major U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, the FDA found in a ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...

The health sector faces a range of global challenges and developments, including Indian tax proposals, trade impacts on Brazilian chicken exports, and activist investment in Gerresheimer. Other key ...